Steven M Larson, Richard J Robbins
Journal: Best practice & research. Clinical endocrinology & metabolism 2009;22(6):1047-59
PMID: 19041831
For more than a decade, positron emission tomography (PET) has had an important role in the management of thyroid cancer patients. It may be involved in initial, sometimes inadvertent, diagnosis; in postoperative evaluation; in detection of occult metastases; in the evaluation of thyroid nodules; and in prognostication of metastatic disease. In this review we will update the advances in the application of PET scanning to optimal patient management. The majority of the published studies to date have used 18F-fluoro-deoxyglucose (FDG) as the PET isotope, and unless specifically noted, all references to PET scanning will imply that this tracer has been used.
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.